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For the motion (rebuttal):It is the small fraction sizes that 
need special pleading, not the large ones. 
 
A. Nahum 
Fractionation is a very odd business. The question ought 
really to be "Why should we deliver curative radiotherapy in a 
large number of small doses, thereby prolonging the number 
of treatment days, increasing both patient inconvenience, 
and overall treatment costs?" Given the significant reduction 
in doses to non-target tissues achievable by modern 
conformal external-beam therapy (including intensity 
modulated photons and spot-scanned protons), and the 
recent findings for breast tumours, and probably also for 
prostate, that the α/β for the clonogens is of the same order 
as that for late normal-tissue complications, there are not 
many tumour sites where hyperfractionation is justified. In 
the latter category are only relatively large lung tumours, 
close to the mediastinum, and those tumours in the head & 
neck region where 'serial' normal tissues (e.g. spinal cord) are 
dose-limiting. Otherwise the onus is on the 'hyper-
fractionators' to justify, to both administrators and patients, 
the vast number of daily visits they wish to impose on 
patients. One can go further - fraction size/number should be 
tailored to each patient according to the maxim "Deliver the 
minimum number of fractions compatible with a high rate of 
local control and a low rate of complications". Software such 
as 'BioSuite' exists to do exactly this; there are no good 
excuses for not using it. 
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